Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06472869 · ClinicalTrials.gov registry record · NA
Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT06472869: Completed NA study, sponsored by Massachusetts General Hospital.
NCT06472869 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06472869, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study investigates the feasibility, acceptability, and short-term effects of providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did not quit after smoking cessation treatment provided in the context of lung cancer screening and do not plan to quit smoking. This open-label single-arm pilot clinical trial will test the impact of EC provision on: 1) study feasibility, 2) EC acceptability, 3) tobacco use behavior (e.g., cigarettes per day, EC use), and 4) biomarkers (e.g., carbon monoxide, cotinine, and anabasine). Participants will be asked to switch from combustible cigarettes to the NJOY ACE 5% nicotine electronic cigarette (EC) for 4 weeks. They will be followed an additional 4 weeks after EC provision ends (to 8 weeks). The first study hypothesis is that more than 40% of eligible smokers who are offered participation in the trial will enroll, and that 75% of enrollees will complete the trial. The second study hypothesis is that participants will report fewer cigarettes smoked per day at the end of 4 weeks of EC provision, relative to their baseline values.
Interventions
- OTHER NJOY ACE e-cigarette
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06472869
The ClinicalTrials.gov registry entry for NCT06472869 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NJOY ACE e-cigarette is the first listed.
NCT06472869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06472869 about?
NCT06472869 is a clinical study titled "Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening". This study investigates the feasibility, acceptability, and short-term effects of providing 4 weeks of complimentary electronic cigarettes (ECs) to 30 individuals who did not quit after smoking cessation treatment provided in the context of lung cancer screening and do not plan to quit smoking. This...
What is the current status of trial NCT06472869?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2024-09-23. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT06472869?
The interventions under investigation include: NJOY ACE e-cigarette (OTHER).
Who is sponsoring clinical trial NCT06472869?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.